Mitomycin medac
Intravesical cytotoxic agent for bladder cancer recurrence prevention
Mitomycin medac is a cytotoxic (anticancer) medication used intravesically – instilled directly into the bladder – to prevent the recurrence of superficial bladder cancer following surgical removal of tumour tissue. This prescription-only medicine works by inhibiting DNA synthesis in rapidly dividing cancer cells and is administered exclusively by trained healthcare professionals in a clinical setting.
Quick Facts
Key Takeaways
- Mitomycin medac is a cytotoxic antibiotic instilled directly into the bladder to prevent recurrence of superficial bladder cancer after transurethral resection (TUR).
- It is administered only by trained healthcare professionals in a hospital or clinic setting – not a medication you take at home.
- The solution remains in the bladder for 1–2 hours, during which patients should change position regularly to maximise contact with the bladder lining.
- Common side effects include bladder inflammation, painful urination, blood in urine, and skin rashes, but serious systemic effects are rare with intravesical use.
- Mitomycin must not be used during pregnancy or breastfeeding. Effective contraception is required during treatment and for 6 months after.
What Is Mitomycin medac and What Is It Used For?
Mitomycin medac belongs to a group of medicines known as cytotoxic antibiotics or antineoplastic agents. These substances prevent or significantly delay cell division by affecting cellular metabolism in various ways. In cancer treatment, cytotoxic agents exploit the fact that cancer cells differ from normal cells, particularly through their more rapid and uncontrolled division.
The active ingredient, mitomycin, was originally isolated from the bacterium Streptomyces caespitosus and has been used in oncology for decades. It functions as a bioreductive alkylating agent, meaning it is activated inside cells where oxygen levels are low – a common characteristic of tumour tissue. Once activated, mitomycin forms cross-links between the two strands of DNA, which prevents the DNA from separating during cell division, effectively blocking cancer cell replication.
In the specific formulation of Mitomycin medac, the drug is prepared as a powder that is dissolved in sterile sodium chloride solution and instilled directly into the bladder (intravesical administration). This localised approach ensures high drug concentrations at the target site – the bladder mucosa – while minimising systemic exposure and therefore reducing the risk of widespread side effects compared to intravenous chemotherapy.
Therapeutic Indication
Mitomycin medac is indicated for the prophylaxis (prevention) of recurrence of superficial bladder cancer following transurethral resection (TUR). TUR is a surgical procedure in which cancerous tissue is removed from the bladder lining through the urethra. Despite successful surgery, superficial bladder cancer has a well-documented tendency to recur, with recurrence rates of 50–70% within five years without adjuvant therapy. Intravesical mitomycin significantly reduces this recurrence risk.
According to the European Association of Urology (EAU) guidelines, a single immediate postoperative instillation of intravesical chemotherapy is recommended for all patients with suspected non-muscle-invasive bladder cancer (NMIBC), and mitomycin is one of the most commonly used agents for this purpose. For intermediate-risk tumours, additional maintenance instillations may be recommended.
The World Health Organization (WHO) includes mitomycin on its Model List of Essential Medicines, reflecting the drug’s critical importance in global oncology practice. It is approved throughout the European Economic Area and is widely available internationally under similar trade names.
Mitomycin may also be approved for other medical conditions not specifically described in this patient information. Always follow your prescribing physician’s instructions and consult your healthcare provider if you have further questions about its use.
What Should You Know Before Using Mitomycin medac?
Only physicians with experience in this type of cancer treatment will prescribe Mitomycin medac. Your doctor will determine which treatment regimen is most appropriate for your individual situation, taking into account your tumour characteristics, overall health status, and risk factors for recurrence.
Contraindications
- You are allergic to mitomycin or any of the other ingredients (urea, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections)
- You are breastfeeding – breastfeeding must be discontinued during treatment
- You have a perforated bladder wall – any break in the bladder lining could allow mitomycin to enter surrounding tissues, causing severe harm
- You have an active bladder infection (cystitis) – the inflamed bladder wall may allow increased systemic absorption
Warnings and Precautions
Speak with your doctor or pharmacist before using Mitomycin medac. Special care is required in the following situations:
- Poor general health status: Your doctor will carefully assess whether the benefits outweigh the risks.
- Impaired lung, kidney, or liver function: Pre-existing organ impairment may increase the risk of complications. Baseline monitoring may be necessary.
- Concurrent radiotherapy: Radiation combined with mitomycin may increase the risk of bone marrow suppression and tissue toxicity.
- Treatment with other cytotoxic agents: Concurrent chemotherapy may compound toxic effects on blood-forming tissues.
- Bone marrow depression: Mitomycin can worsen existing bone marrow suppression, reducing blood cell production. This is particularly concerning for elderly patients and those on prolonged therapy.
- Fertility concerns: Mitomycin may permanently impair your ability to have children. Discuss fertility preservation before starting treatment.
Inform your doctor immediately if you experience abdominal or pelvic pain occurring immediately after, or weeks to months following, intravesical administration. Your doctor may need to perform an abdominal ultrasound to investigate potential drug leakage outside the bladder.
Mitomycin is classified as a mutagenic and potentially carcinogenic substance that can cause significant hereditary changes in genetic material. Avoid all direct contact with the drug on skin and mucous membranes. After instillation, sit down when urinating to avoid splashing, and wash your hands and genital area after urination – especially the first time you urinate after treatment.
Children and Adolescents
The use of Mitomycin medac in children and adolescents (under 18 years) is not recommended. There is insufficient clinical evidence regarding safety and efficacy in this age group, and superficial bladder cancer is exceptionally rare in paediatric populations.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before receiving this medicine.
Pregnancy: Mitomycin can cause hereditary genetic damage and has documented negative effects on foetal development. You must not become pregnant during treatment. If pregnancy occurs, genetic counselling is essential. Mitomycin must not be used during pregnancy unless the treating physician determines the benefit clearly outweighs potential risk to the unborn child.
Breastfeeding: Mitomycin is likely excreted in breast milk. Breastfeeding must be stopped during treatment with Mitomycin medac.
Contraception and Fertility: Sexually mature patients of both sexes must use effective contraception or abstain from sexual activity during treatment and for at least 6 months afterwards. Male patients should seek advice regarding sperm preservation before therapy, due to the risk of irreversible infertility.
Driving and Operating Machinery
Even when used as directed, this medicine may cause nausea and vomiting that could impair reaction times sufficiently to affect your ability to drive or operate machinery. This applies particularly in combination with alcohol. You are personally responsible for assessing whether you are fit to drive after receiving treatment.
How Does Mitomycin medac Interact with Other Drugs?
The intravesical route means the drug acts locally within the bladder with minimal systemic absorption. Clinically meaningful drug interactions are therefore not expected when mitomycin is used exclusively via bladder instillation. Nevertheless, always inform your healthcare provider about all medications, supplements, and herbal products you are taking.
Interactions Relevant to Intravenous Administration
The following interactions are primarily relevant when mitomycin is administered intravenously (a different route), but are included for completeness as some patients may receive concurrent systemic therapies:
| Interacting Drug | Effect | Severity |
|---|---|---|
| Vinca alkaloids (e.g. vincristine, vinblastine) | Enhanced pulmonary (lung) toxicity | Major |
| Bleomycin | Enhanced pulmonary toxicity | Major |
| 5-Fluorouracil | Increased risk of haemolytic uraemic syndrome (HUS) | Major |
| Tamoxifen | Increased risk of haemolytic uraemic syndrome (HUS) | Major |
| Doxorubicin (Adriamycin) | Enhanced cardiotoxicity (heart damage) | Major |
| Vitamin B6 (Pyridoxine) | May reduce mitomycin effectiveness (animal data) | Moderate |
| Live vaccines | Increased risk of infection from the live vaccine | Major |
| Other myelosuppressive agents | Enhanced bone marrow suppression | Major |
You should not receive live vaccines during treatment with mitomycin, as this may increase your risk of vaccine-related infection. Discuss your vaccination schedule with your healthcare team before starting treatment. Inactivated vaccines are generally considered safe.
What Is the Correct Dosage of Mitomycin medac?
Mitomycin medac is administered exclusively by trained healthcare professionals. The drug is never self-administered. Numerous intravesical mitomycin regimens exist, varying in dose, frequency, and duration, and your urologist or oncologist will select the protocol best suited to your tumour characteristics and risk profile.
Standard Dosage
Adults – Intravesical Instillation
Standard dose: 40 mg dissolved in 40 ml of 0.9% sodium chloride solution (1 mg/ml)
Frequency: Once weekly (most common). Alternatives: every two weeks, monthly, or every three months for maintenance.
Retention time: 1–2 hours in the bladder
Duration: Individually determined, ranging from a single postoperative instillation to maintenance courses lasting up to one year.
Administration Procedure
The administration follows a standardised procedure for safety and efficacy:
- Bladder preparation: The bladder is emptied via catheter. Do not use the toilet immediately before your appointment.
- Drug reconstitution: The 40 mg powder is dissolved in 40 ml sterile 0.9% sodium chloride solution. The solution must form a clear blue-purple solution within 2 minutes.
- Instillation: The solution is introduced into the empty bladder through a catheter under low pressure.
- Retention period: The solution remains for 1–2 hours. Change position every 15 minutes (back, left side, right side, front) to ensure full mucosal contact.
- Voiding: After 2 hours, empty your bladder in a seated position to avoid splashing.
Limit fluid intake before, during, and after instillation to reduce dilution of the mitomycin by urine production. An optimal urinary pH above 6 improves drug stability and effectiveness.
Children and Adolescents
Not recommended for patients under 18 years. No established dosing recommendations exist for this population.
Elderly Patients
No specific dose adjustments required based on age. However, elderly patients may be more susceptible to bone marrow depression. Regular blood count monitoring is recommended.
Missed Dose
Since treatment is administered by healthcare professionals, contact your clinic to reschedule if you miss an appointment. Do not compensate with a double dose.
Overdose
If accidental overdose occurs, symptoms may include fever, nausea, vomiting, and blood count changes. Supportive treatment will be provided. The risk is very low as the drug is always administered by trained professionals.
What Are the Side Effects of Mitomycin medac?
Like all medicines, Mitomycin medac can cause side effects, although not everyone experiences them. Because the drug acts locally within the bladder with minimal systemic absorption, side effects tend to be concentrated in the urinary tract and surrounding skin.
- Severe allergic reaction: dizziness, skin rash or hives, itching, swelling of lips/face/airways, breathing difficulties, loss of consciousness
- Serious lung disease: unexplained breathlessness, dry cough, crackling sounds when breathing in
- Severely impaired kidney function: producing little or no urine
These are very rare but require immediate discontinuation of treatment.
Side Effects After Intravesical Administration
Common
May affect up to 1 in 10 people
- Bladder inflammation (cystitis), sometimes with blood
- Painful urination (dysuria)
- Frequent urination at night (nocturia)
- Very frequent urination (pollakiuria)
- Blood in urine (haematuria)
- Local irritation of the bladder wall
- Local skin rash (exanthema)
- Allergic skin rash
- Contact dermatitis from mitomycin
- Numbness, swelling and painful redness of palms and soles (palmoplantar erythema)
Rare
May affect up to 1 in 1,000 people
- Widespread skin rash (generalised exanthema)
Very Rare
May affect up to 1 in 10,000 people
- Necrotising cystitis (severe bladder inflammation with tissue death)
- Eosinophilic cystitis (allergic bladder inflammation)
- Urinary tract stenosis (narrowing)
- Reduced bladder capacity
- Bladder wall calcification
- Bladder wall fibrosis (scar tissue formation)
- Decreased white blood cells (leucopenia)
- Decreased platelets (thrombocytopenia)
- Systemic allergic reactions
- Interstitial lung disease
- Elevated liver enzymes
- Hair loss (alopecia)
- Nausea and vomiting
- Diarrhoea
- Impaired kidney function
- Fever
Complications from Extravasation
If mitomycin unintentionally reaches areas outside the bladder (e.g. due to undetected perforation), serious complications may occur:
- Direct bladder damage
- Abdominal abscess
- Fat tissue necrosis in the surrounding area
- Bladder fistula
Side Effects with Intravenous Administration (Different Route)
For comprehensive awareness, the following effects occur when mitomycin is used intravenously. These are substantially more common due to systemic drug exposure:
Very Common (IV route)
May affect more than 1 in 10 people
- Bone marrow suppression (myelosuppression)
- Decreased white blood cells (leucopenia)
- Decreased platelets (thrombocytopenia)
- Nausea and vomiting
Common (IV route)
May affect up to 1 in 10 people
- Interstitial pneumonia
- Breathing difficulties, cough, breathlessness
- Skin rash, contact dermatitis
- Palmoplantar erythema
- Kidney disorders (nephrotoxicity)
- Cellulitis or tissue necrosis at injection site
Uncommon (IV route)
May affect up to 1 in 100 people
- Mucositis, stomatitis
- Diarrhoea
- Hair loss (alopecia)
- Fever
- Loss of appetite
Rare (IV route)
May affect up to 1 in 1,000 people
- Life-threatening infections, sepsis
- Haemolytic anaemia
- Thrombotic thrombocytopenic purpura
- Heart failure (after prior anthracycline therapy)
- Pulmonary hypertension
- Pulmonary veno-occlusive disease
- Liver impairment, jaundice, hepatic veno-occlusive disease
- Haemolytic uraemic syndrome (HUS)
- Microangiopathic haemolytic anaemia (MAHA)
Reporting suspected adverse reactions after authorisation is essential for ongoing safety monitoring. Report to your national medicines regulatory authority (e.g. EMA, FDA, MHRA).
How Should You Store Mitomycin medac?
Keep out of sight and reach of children. Do not use after the expiry date on the label (last day of the stated month). No special temperature requirements for unopened product, but store the vial in the outer carton to protect from light.
After Reconstitution
- Room temperature (15–25°C), protected from light: Stable for up to 48 hours
- Refrigerated (2–8°C), protected from light: Stable for up to 72 hours
- Microbiological recommendation: Use immediately after reconstitution
If not used immediately, storage should not exceed 24 hours at 2–8°C unless prepared under validated aseptic conditions. Do not administer the solution at refrigerated temperature, as cold solution may trigger premature urination urge, reducing drug exposure time. Allow to reach room temperature before instillation.
As a cytotoxic agent, mitomycin requires special disposal. Do not dispose via wastewater or household waste. Ask your pharmacist or healthcare facility about proper disposal procedures.
What Does Mitomycin medac Contain?
Active Substance
The active substance is mitomycin. Each vial contains 40 mg mitomycin. After reconstitution with 40 ml diluent, each millilitre contains 1 mg mitomycin.
Excipients
Powder: Urea (stabiliser)
Diluent: Sodium chloride (0.9% isotonic solution), water for injections, pH-adjusting agents (1 M sodium hydroxide, 1 M hydrochloric acid)
Appearance and Pack Sizes
Grey to greyish-blue powder in clear glass vials. Diluent is a clear, colourless solution in advanced polypropylene (APP) bags. Reconstituted solution should be clear blue-purple.
Available as instillation kits:
- Pack sizes: 1, 4, or 5 glass vials (50 ml) with rubber stoppers and aluminium seals
- Diluent: Matching APP bags containing 40 ml of 0.9% sodium chloride
- Accessories: May include Luer-Lock catheters, lubricant, connectors, and waste bags depending on configuration
Not all pack sizes may be available in all countries.
Marketing Authorisation Holder
medac Gesellschaft fur klinische Spezialpraparate mbH, Theaterstr. 6, 22880 Wedel, Germany. Tel: +49 4103 8006-0
Authorised throughout the European Economic Area as Mitomycin medac (most countries), mito-extra (Germany), Miturox (Italy), and Mitomicina medac (Portugal, Slovenia).
Frequently Asked Questions About Mitomycin medac
Mitomycin medac is instilled directly into the bladder to prevent recurrence of superficial bladder cancer after transurethral resection (TUR). Without adjuvant therapy, recurrence rates reach 50–70% within five years. Intravesical mitomycin significantly reduces this risk according to meta-analyses and international guidelines from the EAU and NCCN.
Trained healthcare professionals dissolve the 40 mg powder in 40 ml sterile sodium chloride solution and instil it into the bladder via a catheter. Limit fluid intake beforehand. The solution stays in the bladder for 1–2 hours while you change position every 15 minutes. After 2 hours, empty your bladder while sitting down.
Common side effects (up to 1 in 10 patients) include bladder inflammation (cystitis), painful urination, frequent urination, blood in urine, local bladder wall irritation, and skin reactions including contact dermatitis. Serious systemic side effects like bone marrow suppression are very rare with intravesical use.
No clinically significant interactions have been documented for the intravesical route due to minimal systemic absorption. However, always inform your healthcare team about all medications, supplements, and herbal products. If you are also receiving intravenous chemotherapy, additional interaction considerations apply.
Each session takes approximately 2–3 hours total: catheterisation and instillation (15–30 minutes), retention period (1–2 hours), and voiding afterwards. Restrict fluid intake before and during the procedure to maintain drug concentration.
No. Mitomycin must not be used during pregnancy or breastfeeding. It has mutagenic and teratogenic potential. Both women and men of reproductive age must use effective contraception during and for 6 months after treatment. Men should consider sperm banking before therapy due to risk of irreversible infertility.
References
- European Association of Urology (EAU). EAU Guidelines on Non-muscle-invasive Bladder Cancer. 2024 Edition.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines: Bladder Cancer. Version 3.2024.
- European Medicines Agency (EMA). Mitomycin medac – Summary of Product Characteristics. Last revised 2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List (2023).
- Sylvester RJ, et al. Systematic review and IPD meta-analysis of single immediate instillation of chemotherapy after TUR. European Urology. 2016;69(2):231-244.
- Shelley MD, et al. Systematic review of intravesical BCG plus TUR vs TUR alone in Ta and T1 bladder cancer. BJU International. 2001;88(3):209-216.
- British National Formulary (BNF). Mitomycin. NICE. Updated 2024.
- Huncharek M, et al. Impact of intravesical chemotherapy on recurrence rate of superficial bladder cancer. Anticancer Research. 2001;21(1B):765-769.
Editorial Team
Reviewed by the iMedic Medical Review Board: board-certified specialists in oncology, urology, and clinical pharmacology. Content follows the GRADE framework and adheres to EAU, NCCN, WHO, and EMA guidelines.
No commercial funding or pharmaceutical sponsorship. All medical claims supported by peer-reviewed evidence. Editorial process includes fact-checking against primary sources, expert review, and regular updates.
Last medical review: | Published: